Annexin-based apoptosis markers
The present invention describes an annexin derivative and a method of using the annexin derivative as a biosensor for real-time visualization of phosphatidylserine exposure, apoptosis, live-cell imaging and monitoring of cell health.
1. An annexin derivative, comprising:
the amino acid sequence of SEQ ID NO: 1 wherein residues 101 and 260 of SEQ ID NO: 1 have been substituted with cysteine residues, wherein said cysteine residues are conjugated to polarity sensitive fluorophore N,N′-Dimethyl-N-(iodoacetyl)-N′(7-nitrobenz-2-oxa-1,2-diazol-4-yl)ethylenediamine (IANBD) or 6-Bromoacetyl-2-dimethylaminonaphthalene (BADAN), and wherein residues 113 and 302 of SEQ ID NO: 1 are substituted with an amino acid other than cysteine or lysine.
2. The annexin derivative of claim 1 , wherein the polarity sensitive fluorophore is N,N′-Dimethyl-N-(iodoacetyl)-N′(7-nitrobenz-2-oxa-1,2-diazol-4-yl)ethylenediamine (IANBD).
3. The annexin derivative of claim 1 , wherein the polarity sensitive fluorophore is 6-Bromoacetyl-2-dimethylaminonaphthalene (BADAN).
4. A method of detecting apoptosis, comprising: contacting the annexin derivative of claim 1 to a sample comprising cells; and detecting a fluorescence resulting from the fluorophore in the sample.
5. The method of claim 4 , wherein detecting the fluorescence comprises detecting an increase of fluorescence intensity and/or a shift in the wavelength of the fluorescence.
6. The method of claim 5 , wherein the increase of fluorescence intensity is one or more orders of magnitude.
7. The method of claim 5 , wherein the polarity sensitive fluorophore is N,N′-Dimethyl-N-(iodoacetyl)-N′(7-nitrobenz-2-oxa-1,2-diazol-4-yl)ethylenediamine (IANBD) and the fluorescence is detected at a λ max of about 500 to about 600 nm.
8. The method of claim 7 , wherein detection is performed in a real time fluorescence detection and/or performed in a high-throughput screening system.
9. The method of claim 5 , wherein the polarity sensitive fluorophore is 6-Bromoacetyl-2-dimethylaminonaphthalene (BADAN) and the fluorescence is detected in the blue light range from 420 nm to 470 nm.
10. The method of claim 9 , wherein the detection of the fluorescence is performed in a real time fluorescence detection and/or in a high-throughput screening system.
11. A method of monitoring cell health, comprising:
contacting the annexin derivative of claim 1 to a sample comprising cells; and
monitoring the fluorescence resulting from the fluorophore, wherein an increase in the fluorescence intensity and/or a shift in the wavelength of the fluorescence indicate that a cell is undergoing apoptosis and an absence of an increase in the fluorescence intensity and/or an absence of a shift in the wavelength of the fluorescence indicate that a cell is healthy.
12. The method of claim 11 , further comprising administering a therapeutic drug upon detection of one or more cells undergoing apoptosis.
13. The method of claim 11 , wherein the polarity sensitive fluorophore is N,N′-Dimethyl-N-(iodoacetyl)-N′(7-nitrobenz-2-oxa-1,2-diazol-4-yl)ethylenediamine (IANBD).
14. The method of claim 13 , wherein detection is performed in a real time fluorescence detection and/or in a high-throughput screening system.
15. The method of claim 11 , wherein the polarity sensitive fluorophore is 6-Bromoacetyl-2-dimethylaminonaphthalene (BADAN).
16. A kit comprising: an annexin derivative comprising the amino acid sequence of SEQ ID NO:1 wherein residues 101 and 260 of SEQ ID NO:1 have been substituted with cysteine residues and said cysteine residues are conjugated to a polarity sensitive fluorophore N,N′-Dimethyl-N-(iodoacetyl)-N′(7-nitrobenz-2-oxa-1,2-diazol-4-yl)ethylenediamine (IANBD) or 6-Bromoacetyl-2-dimethylaminonaphthalene (BADAN), and wherein residues 113 and 302 of said SEQ ID NO:1 are substituted with an amino acid other than cysteine or lysine; and instructions for using the annexin derivative to detect phosphatidylserine exposure.
17. The kit of claim 16 , wherein the annexin derivative is in a cell culture medium.